Author of

• 11794

  +

  P2.12 - Poster Session 2 - NSCLC Early Stage (ID 205)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11813

    +

    P2.12-019 - Compliance, toxicity and successfull goals in adjuvant setting. Results from Two Referal Centers in South America. (ID 2790)

    09:30 - 09:30  |  Author(s): M. Luongo
    • Abstract

    Background
    Cisplatin based chemotherapy is the treatment of choice in the adjuvant setting of non small cell cancer (NSCLC) stages (IB)II-IIIA. Compliance, toxicity and follow up are issues of paramount importance. Series from Latinamerica were infrecuent.

    Methods
    We retrospectively analyzed all patients with NSCLC diagnosis and adjuvant treatment at two referal center since 2008 to present. Toxicity, compliance and follow up were the end point.

    Results
    The medical records of forty five consecutive patients were reviewed. Median Age was 60 (r.40-76).From 45 patients twenty five (55,6%) were male and twenty (44,4%) female. Stage IB four patients (8,8%), teen patients were stage IIA (22,2%), 15(33,3%) were IIB and 16 (35,56%) patients stage IIIA . Pathology was adenocarcinoma 33 patients (pts) , squamous cell carcinoma in teen cases and other pathology in 2 cases.Perfomance Status at start of treatment were 0 in teen pts, 1 thirty two pts and 2 in three. All patients had accessibility (with or without insurance). The median days to start chemotherapy since surgery was 37.Regimes indicated were Cisplatin-Vinorelbine (29), Cisplatin-VP-16 (9), Carboplatin-Paclitaxel (4) and others 3.The median number of cycles were 4 (3-6). The Cisplatin-Vinorelbine regimen was completed in 62% of pts and related with more adverse events,others combo were completed with mild toxicity in 66,6% of cases. No Grade 5 toxicity were recorded. Toxicity were recorded in 35 medical records.Grade 3-4 were seen in 16 pts (45,7%), the toxicity more frequent was asthenia (12pts),neurotoxicity (8pts),pain at administration site (5pts) all with vinorelbine,febril neutropenia in 7 pts, trombocytopenia and neutropenia in 12 pts and anemia 10 pts. Recurrence was seen in 10/45 pts ,the pattern of recurrence were locoregional 4 pts and distant 6 pts. No second tumors were reported and three lung cancers with different histology were recorded at follow up in 3pts.

    Conclusion
    Adjuvant treatment of NSCLC were feasible, with high compliance and mild toxicity in the community setting. The multidisciplinary approach for thoracic oncology teams in the follow up and surveillance of adverse events is the target in this population.